CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
CBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
BBCR::ABL1Fusion AND ABL1 Y253HPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
BBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 M244VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 F359VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CBCR::ABL1Fusion AND ABL1 E459KPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinib MesylateGuilhot et al., 2007
CSNX2::ABL1FusionPredictiveSupportsReduced SensitivityB-lymphoblastic Leukemia/lymphomaImatinibErnst et al., 2011
ABRCA1MutationPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparibMoore et al., 2018
CFOXP1::ABL1FusionPredictiveSupportsSensitivity/ResponseB-lymphoblastic Leukemia/lymphomaDasatinibYenamandra et al., 2019
BMETExon 14 Skipping MutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinibAlexander E. Drilon, 2016, ASCO Annual Meeting, Abstract 108
CFOXP1::ABL1FusionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeBoer et al., 2017
CSNX2::ABL1FusionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaMu et al., 2017
CSNX2::ABL1FusionPrognosticSupportsPoor OutcomeB-lymphoblastic Leukemia/lymphomaMasuzawa et al., 2014
CBCR::ABL1Fusion AND ABL1 D363GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 E98GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 M244VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 L364IPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibTalpaz et al., 2006
DLYNOVEREXPRESSIONPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibDeguchi et al., 2008
CBCR::ABL1Fusion AND ABL1 F359VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
DPIK3CAE542KPredictiveSupportsResistanceBreast CancerPI-103O'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsResistanceBreast CancerPI-103O'Brien et al., 2010
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPI-103O'Brien et al., 2010
DPIK3CAK111NPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI-103O'Brien et al., 2010
DPTENLossPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI-103O'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAE545KPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAH1047LPredictiveSupportsSensitivity/ResponseBreast CancerPI3Ka/DiO'Brien et al., 2010
DPIK3CAK111NPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DPTENLossPredictiveSupportsResistanceHer2-receptor Positive Breast CancerPI3Ka/DiO'Brien et al., 2010
DLMNA::NTRK1FusionOncogenicSupportsOncogenicityColorectal CancerSartore-Bianchi et al., 2016
CZMIZ1::ABL1FusionOncogenicSupportsOncogenicityB-lymphoblastic Leukemia/lymphomaSoler et al., 2008
CCHD7::BEND2FusionOncogenicSupportsOncogenicityPancreatic Endocrine CarcinomaWilliamson et al., 2019
CEGFRN771_P772insLPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibFang et al., 2019
DPIK3R2G373RFunctionalSupportsGain of FunctionRivière et al., 2012
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseChildhood EpendymomaLapatinibFouladi et al., 2010
CFLCNc.1285dupCPredictiveSupportsSensitivity/ResponseRenal Cell CarcinomaEverolimusNakamura et al., 2013
DEGFRR252CFunctionalSupportsUnaltered FunctionNg et al., 2018
DFGFR3K650EFunctionalSupportsGain of FunctionBellus et al., 2000
CEML4::NTRK3FusionOncogenicSupportsOncogenicityCervical SarcomaDang et al., 2022
CEML4::NTRK3FusionOncogenicSupportsOncogenicityPancreatic Ductal AdenocarcinomaAllen et al., 2023
CEML4::NTRK3FusionOncogenicSupportsOncogenicityColon AdenocarcinomaSolomon et al., 2020
CEML4::NTRK3FusionOncogenicSupportsOncogenicityGlioblastomaSolomon et al., 2020
CEML4::NTRK3FusionOncogenicSupportsOncogenicityPoorly Differentiated Thyroid CarcinomaSolomon et al., 2020
CKANK1::NTRK2FusionOncogenicSupportsOncogenicityBrain Glioblastoma MultiformeSolomon et al., 2020
DSMAD2S276LFunctionalSupportsLoss of FunctionFleming et al., 2013
BEZH2Activating MutationPredictiveSupportsSensitivity/ResponseFollicular LymphomaTazemetostatMunakata et al., 2021
Page 94 of 96
PreviousNext